Nadia B. Hassounah

Tris Pharma (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

8h-index671citations45works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic and Kidney Cyst Diseases(16), Hedgehog Signaling Pathway Studies(12), Cancer Immunotherapy and Biomarkers(8), Epigenetics and DNA Methylation(8), Chronic Lymphocytic Leukemia Research(6)

Publications45 total

Supplementary Figure S1 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Data from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S8 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Methods S1 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Tables S1-S10 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S5 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S9 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S6 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S3 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S7 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S10 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S2 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S4 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
Clinical Cancer Research·2025
A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies
ESMO Open·2024· 8 citedOpen Access
A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies
Blood·2023· 3 cited
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
Journal for ImmunoTherapy of Cancer·2023· 22 citedOpen Access
695P A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma
Annals of Oncology·2023· 3 citedOpen Access
Abstract CT021: Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib
Cancer Research·2023· 2 cited
Supplementary Table 1 from Inhibition of Ciliogenesis Promotes Hedgehog Signaling, Tumorigenesis, and Metastasis in Breast Cancer
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Ian W. Flinn(17), Kimberly M. McDermott(16), Anwesha Chaudhury(16), Carolyn McGarry(16), Sarah M. Larson(16), Laura Martz(15), Huabao Wang(15), Ethan Hopping(15), Alexandra Acosta(15), Daniela Baldoni(15), Jeanne Whalen(15), Nina Orwitz(15), Kerry A. Rogers(14), Janghee Woo(14), Altan Turkoglu(14), Romain Séchaud(14), Ray B. Nagle(13), Deborah M. Stephens(13), Thomas J. Kipps(13), Denise J. Roe(12)